Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group
Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1. The new...
Dela artikeln
Taggar: hamlet, pharma, secures
Läs vidare på Dagens IndustriRelaterade nyheter
- Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET
- Hamlet Pharma secures a new Alpha1H production batch for continued clinical trials
- Hamlet Pharmas resultat försämrades
- Kommuniké Från Extra Bolagsstämman i Hamlet Pharma AB